Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone

@article{Harvey2011PerformanceAI,
  title={Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone},
  author={Philip D. Harvey and Masaaki Ogasa and Josephine B. Cucchiaro and Antony Loebel and Richard S. E. Keefe},
  journal={Schizophrenia Research},
  year={2011},
  volume={127},
  pages={188-194}
}

Figures and Tables from this paper

The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition.

The CAI appears to provide useful complementary information and possesses practical advantages for rating cognitive functioning including an interview-based method of administration, brief assessment time, little or no practice effects, and ease of scoring.

Correlation between Performance-Based and Interview-Based Cognitive Measurements in Patients with Schizophrenia

Correlations between MCCB domains and SCoRS items are revealed, and interview-based measurements are suggested as a useful cognitive function evaluation tool that can easily be applied in clinical settings.

Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale

Validation of the Chinese Version of the Schizophrenia Cognition Rating Scale

The Chinese version of SCoRS showed good discriminant, concurrent, and external validity, suggesting that it is a useful and convenient tool for assessment of cognitive function among Mandarin-speaking patients with schizophrenia in clinical practice.

Validating the measurement of real-world functional outcomes: phase I results of the VALERO study.

Of the six rating scales evaluated in this study, the Specific Levels of Functioning Assessment was the best and provided an efficient assessment of real-world functioning that accounts for considerable variance in performance-based scores.

[Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine].

Lurasidone demonstrated significant improvement for both PANSS total score and each of the five PANSS factor scores, indicating effectiveness across the broad spectrum of schizophrenia symptoms.

[Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine].

Lurasidone demonstrated significant improvement for both PANSS total score and each of the five PANSS factor scores, indicating effectiveness across the broad spectrum of schizophrenia symptoms.
...

References

SHOWING 1-10 OF 37 REFERENCES

The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.

A new interview-based assessment of cognition, the Schizophrenia Cognition Rating Scale (SCoRS), that involves interviews with patients and informants, may be valid coprimary measures for clinical trials assessing cognitive change and may also aid clinicians desiring to assess patients' level of cognitive impairment.

Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.

The authors examined cognitive changes associated with treatment with ziprasidone and olanzapine over a 6-month double-blind clinical trial, using normative standards for the cognitive measures.

A brief cognitive assessment for use with schizophrenia patients in community clinics

Self-assessment of functional status in schizophrenia.

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.

Olanzapine has a beneficial effect on neurocognitive function in patients with a first episode of psychosis, however, in a comparison of the effects of olanzapine and low doses of haloperidol, the difference in benefit is small.

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Cognitive improvements were modest, their clinical importance was suggested by relationships with improvements in functional outcome, and Statistically significant relationships between improvements in neurocognition and functional outcome were observed.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups.